Literature DB >> 28237426

The Role of the Human Visual Cortex in Assessment of the Long-Term Durability of Retinal Gene Therapy in Follow-on RPE65 Clinical Trial Patients.

Manzar Ashtari1, Elena S Nikonova2, Kathleen A Marshall3, Gloria J Young4, Puya Aravand4, Wei Pan5, Gui-Shuang Ying5, Aimee E Willett4, Mani Mahmoudian4, Albert M Maguire6, Jean Bennett6.   

Abstract

PURPOSE: Gene therapy (GT) has offered immense hope to individuals who are visually impaired because of RPE65 mutations. Although GT has shown great success in clinical trials enrolling these individuals, evidence for stability and durability of this treatment over time is still unknown. Herein we explored the value of functional magnetic resonance imaging (fMRI) as an objective measure to assess independently the longevity of retinal GT.
DESIGN: Individuals with RPE65 mutations who underwent GT in their worse-seeing eye in a phase 1 clinical trial received a second subretinal injection in their contralateral eye in a follow-on clinical trial. Functional magnetic resonance imaging (MRI) was performed longitudinally to assess brain responses of patients with RPE65 mutations after stimulation of their most recently treated eye before and 1 to 3 years after GT. PARTICIPANTS: Seven participants with RPE65 mutations who were part of the follow-on clinical trial gave informed consent to participate in a longitudinal neuroimaging fMRI study.
METHODS: All participants underwent fMRI using a 3-Tesla MRI system and a 32-channel head coil. Participants' cortical activations were assessed using a block design paradigm of contrast reversing checkerboard stimuli delivered using an MRI-compatible video system. MAIN OUTCOME MEASURES: The primary parameters being measured in this study were the qualitative and quantitative fMRI cortical activations produced by our population in response to the visual task.
RESULTS: Functional MRI results showed minimal or no cortical responses before GT. Significant increase in cortical activation lasting at least 3 years after GT was observed for all participants. Repeated measures analysis showed significant associations between cortical activations and clinical measures such as full-field light sensitivity threshold for white, red, and blue colors; visual field; and pupillary light reflex.
CONCLUSIONS: Participants with RPE65 mutations showed intact visual pathways, which became responsive and strengthened after treatment. Functional MRI results independently revealed the efficacy and durability of a 1-time subretinal injection. The fMRI results paralleled those recently reported during the long-term clinical evaluations of the same patients. Results from this study demonstrated that fMRI may play an important role in providing complementary information to patients' ophthalmic clinical evaluation and has usefulness as an outcome measure for future retinal intervention studies.
Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28237426      PMCID: PMC5805133          DOI: 10.1016/j.ophtha.2017.01.029

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  39 in total

1.  Early-onset severe rod-cone dystrophy in young children with RPE65 mutations.

Authors:  B Lorenz; P Gyürüs; M Preising; D Bremser; S Gu; M Andrassi; C Gerth; A Gal
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-08       Impact factor: 4.799

2.  Analysis of functional image analysis contest (FIAC) data with brainvoyager QX: From single-subject to cortically aligned group general linear model analysis and self-organizing group independent component analysis.

Authors:  Rainer Goebel; Fabrizio Esposito; Elia Formisano
Journal:  Hum Brain Mapp       Date:  2006-05       Impact factor: 5.038

3.  The organization of projections of the retinorecipient and nonretinorecipient nuclei of the pretectal complex and layers of the superior colliculus to the lateral pulvinar and medial pulvinar in the macaque monkey.

Authors:  L A Benevento; G P Standage
Journal:  J Comp Neurol       Date:  1983-07-01       Impact factor: 3.215

4.  Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel.

Authors:  Eyal Banin; Dikla Bandah-Rozenfeld; Alexey Obolensky; Artur V Cideciyan; Tomas S Aleman; Devora Marks-Ohana; Malka Sela; Sanford Boye; Alexander Sumaroka; Alejandro J Roman; Sharon B Schwartz; William W Hauswirth; Samuel G Jacobson; Itzhak Hemo; Dror Sharon
Journal:  Hum Gene Ther       Date:  2010-11-03       Impact factor: 5.695

5.  Thalamic and other subcortical projections to area MT (visual area of superior temporal sulcus) in the marmoset Callithrix jacchus.

Authors:  W B Spatz
Journal:  Brain Res       Date:  1975-11-28       Impact factor: 3.252

6.  Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.

Authors:  Albert M Maguire; Katherine A High; Alberto Auricchio; J Fraser Wright; Eric A Pierce; Francesco Testa; Federico Mingozzi; Jeannette L Bennicelli; Gui-shuang Ying; Settimio Rossi; Ann Fulton; Kathleen A Marshall; Sandro Banfi; Daniel C Chung; Jessica I W Morgan; Bernd Hauck; Olga Zelenaia; Xiaosong Zhu; Leslie Raffini; Frauke Coppieters; Elfride De Baere; Kenneth S Shindler; Nicholas J Volpe; Enrico M Surace; Carmela Acerra; Arkady Lyubarsky; T Michael Redmond; Edwin Stone; Junwei Sun; Jennifer Wellman McDonnell; Bart P Leroy; Francesca Simonelli; Jean Bennett
Journal:  Lancet       Date:  2009-10-23       Impact factor: 79.321

7.  In utero gene therapy rescues vision in a murine model of congenital blindness.

Authors:  Nadine S Dejneka; Enrico M Surace; Tomas S Aleman; Artur V Cideciyan; Arkady Lyubarsky; Andrey Savchenko; T Michael Redmond; Waixing Tang; Zhangyong Wei; Tonia S Rex; Ernest Glover; Albert M Maguire; Edward N Pugh; Samuel G Jacobson; Jean Bennett
Journal:  Mol Ther       Date:  2004-02       Impact factor: 11.454

8.  Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations.

Authors:  Samuel G Jacobson; Tomas S Aleman; Artur V Cideciyan; Alejandro J Roman; Alexander Sumaroka; Elizabeth A M Windsor; Sharon B Schwartz; Elise Heon; Edwin M Stone
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-12-30       Impact factor: 4.799

9.  The human visual cortex responds to gene therapy-mediated recovery of retinal function.

Authors:  Manzar Ashtari; Laura L Cyckowski; Justin F Monroe; Kathleen A Marshall; Daniel C Chung; Alberto Auricchio; Francesca Simonelli; Bart P Leroy; Albert M Maguire; Kenneth S Shindler; Jean Bennett
Journal:  J Clin Invest       Date:  2011-05-23       Impact factor: 14.808

10.  Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.

Authors:  Francesca Simonelli; Albert M Maguire; Francesco Testa; Eric A Pierce; Federico Mingozzi; Jeannette L Bennicelli; Settimio Rossi; Kathleen Marshall; Sandro Banfi; Enrico M Surace; Junwei Sun; T Michael Redmond; Xiaosong Zhu; Kenneth S Shindler; Gui-Shuang Ying; Carmela Ziviello; Carmela Acerra; J Fraser Wright; Jennifer Wellman McDonnell; Katherine A High; Jean Bennett; Alberto Auricchio
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

View more
  8 in total

1.  Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy.

Authors:  Kristin L Gardiner; Artur V Cideciyan; Malgorzata Swider; Valérie L Dufour; Alexander Sumaroka; András M Komáromy; William W Hauswirth; Simone Iwabe; Samuel G Jacobson; William A Beltran; Gustavo D Aguirre
Journal:  Mol Ther       Date:  2019-09-03       Impact factor: 11.454

Review 2.  Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.

Authors:  Albert M Maguire; Jean Bennett; Elena M Aleman; Bart P Leroy; Tomas S Aleman
Journal:  Mol Ther       Date:  2020-12-03       Impact factor: 11.454

3.  RPE65-associated inherited retinal diseases: consensus recommendations for eligibility to gene therapy.

Authors:  Andrea Sodi; Sandro Banfi; Francesco Testa; Michele Della Corte; Ilaria Passerini; Elisabetta Pelo; Settimio Rossi; Francesca Simonelli
Journal:  Orphanet J Rare Dis       Date:  2021-06-04       Impact factor: 4.123

4.  Comparing Clinical Perimetry and Population Receptive Field Measures in Patients with Choroideremia.

Authors:  Edward H Silson; Tomas S Aleman; Aimee Willett; Leona W Serrano; Denise J Pearson; Andreas M Rauschecker; Albert M Maguire; Chris I Baker; Jean Bennett; Manzar Ashtari
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-07-02       Impact factor: 4.799

Review 5.  Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward.

Authors:  Ashley L Cooney; Paul B McCray; Patrick L Sinn
Journal:  Genes (Basel)       Date:  2018-11-07       Impact factor: 4.096

6.  Compensatory Cross-Modal Plasticity Persists After Sight Restoration.

Authors:  Theresa G Mowad; Aimee E Willett; Mani Mahmoudian; Mikhail Lipin; Armin Heinecke; Albert M Maguire; Jean Bennett; Manzar Ashtari
Journal:  Front Neurosci       Date:  2020-05-12       Impact factor: 4.677

7.  Sight restoration reverses blindness-induced cross-modal functional connectivity changes between the visual and somatosensory cortex at rest.

Authors:  Negin Nadvar; Noelle Stiles; Jeiran Choupan; Vivek Patel; Hossein Ameri; Yonggang Shi; Zhongming Liu; John Jonides; James Weiland
Journal:  Front Neurosci       Date:  2022-09-23       Impact factor: 5.152

8.  Cortical Visual Mapping following Ocular Gene Augmentation Therapy for Achromatopsia.

Authors:  Ayelet McKyton; Edward Averbukh; Devora Marks Ohana; Netta Levin; Eyal Banin
Journal:  J Neurosci       Date:  2021-08-04       Impact factor: 6.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.